According to reports from Moneycontrol, Anthem Biosciences shares were trading at ₹811.65 on Tuesday, marking a 2.19% decline from the previous session. The stock is a constituent of the Nifty Midcap 150 index, reflecting the market's response to recent quarterly results. As of Tuesday morning, investor sentiment toward Anthem Biosciences was assessed as Very Bullish by Moneycontrol analysis, despite the day's price movement.
As reported by Moneycontrol, the company demonstrated robust financial performance with consolidated revenue of ₹2,124.33 crore for the year-ending March 2026, representing a significant increase from ₹1,844.55 crore in March 2025 and ₹1,419.37 crore in March 2024. Net Profit reached ₹591.79 crore in March 2026, up from ₹451.26 crore in March 2025 and ₹367.31 crore in March 2024. The Earnings Per Share (EPS) stood at ₹10.55 in March 2026, compared to ₹8.07 in March 2025 and ₹6.48 in March 2024. The Book Value Per Share (BVPS) improved to ₹54.16 in March 2026 from ₹43.10 in March 2025, while Return on Equity (ROE) was 19.45% in March 2026, slightly higher than 18.72% in March 2025.
According to the latest quarterly data from Moneycontrol, for the quarter-ending June 2026, consolidated revenue was ₹418.22 crore with Net Profit of ₹119.94 crore and EPS of ₹2.13. This represents a significant decline from the strong March 2026 quarter where revenue was ₹610.94 crore and net profit was ₹189.76 crore. The EPS for June 2026 was ₹2.13, compared to ₹3.38 in the March 2026 quarter. The company's Debt to Equity ratio improved to 0.02 in March 2026, indicating minimal reliance on debt, while the P/E ratio stood at 62.20 and P/B ratio was 12.12 as of March 2026.
According to the financial data reported by Moneycontrol, the company maintained excellent operational efficiency with Gross Profit Margin at 46.58% in March 2026, while Operating Margin stood at 40.27%. The Net Profit Margin was 27.85% for the same period. The Debt to Equity ratio was very low at 0.02 in March 2026, indicating minimal reliance on debt. The Cash Flow from Operating Activities was ₹844 crore in March 2026, a significant increase from ₹418 crore in March 2025. The company's Share Capital stood at ₹112 crore and Reserves & Surplus at ₹2,930 crore as of March 2026.
As reported by Moneycontrol, the company has been active in corporate actions, announcing a final dividend of ₹2.00 per share (100%) with an effective date of June 25, 2026. Recent announcements include an Earnings Call Transcript from July 22, 2026, and the submission of voting results from the 20th Annual General Meeting held on the same date. With the stock's last traded price at ₹811.65, Anthem Biosciences continues to navigate market dynamics while maintaining a solid financial foundation, with the company's Current Ratio at 5.54 and Interest Coverage Ratios improved to 143.54 in March 2026, reflecting strong operational efficiency.
